CELLECTIS (ALCLS.PA) Stock Fundamental Analysis
Europe - EPA:ALCLS - FR0010425595 - Common Stock
2.86 EUR
-0.01 (-0.35%)
ALCLS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 74 industry peers in the Biotechnology industry. ALCLS may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, ALCLS is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year ALCLS has reported negative net income.
ALCLS had a negative operating cash flow in the past year.
In the past 5 years ALCLS always reported negative net income.
ALCLS had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
The Return On Assets of ALCLS (-28.30%) is comparable to the rest of the industry.
ALCLS's Return On Equity of -103.16% is in line compared to the rest of the industry. ALCLS outperforms 46.05% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -28.3% | ||
| ROE | -103.16% | ||
| ROIC | N/A |
ROA(3y)-26.82%
ROA(5y)-25.52%
ROE(3y)-79.12%
ROE(5y)-63.67%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ALCLS has a Gross Margin (3.66%) which is comparable to the rest of the industry.
The Profit Margin and Operating Margin are not available for ALCLS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 3.66% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ALCLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
ALCLS has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ALCLS has been increased compared to 5 years ago.
ALCLS has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -0.62, we must say that ALCLS is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -0.62, ALCLS perfoms like the industry average, outperforming 44.74% of the companies in the same industry.
A Debt/Equity ratio of 0.91 indicates that ALCLS is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.91, ALCLS is doing worse than 61.84% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.91 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.62 |
ROIC/WACCN/A
WACC6.25%
2.3 Liquidity
A Current Ratio of 1.38 indicates that ALCLS should not have too much problems paying its short term obligations.
With a Current ratio value of 1.38, ALCLS is not doing good in the industry: 65.79% of the companies in the same industry are doing better.
A Quick Ratio of 1.38 indicates that ALCLS should not have too much problems paying its short term obligations.
ALCLS's Quick ratio of 1.38 is in line compared to the rest of the industry. ALCLS outperforms 40.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.38 | ||
| Quick Ratio | 1.38 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 70.80% over the past year.
ALCLS shows a strong growth in Revenue. In the last year, the Revenue has grown by 435.37%.
ALCLS shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.44% yearly.
EPS 1Y (TTM)70.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%104.35%
Revenue 1Y (TTM)435.37%
Revenue growth 3Y8.44%
Revenue growth 5Y16.44%
Sales Q2Q%105.87%
3.2 Future
ALCLS is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -53.96% yearly.
Based on estimates for the next years, ALCLS will show a very strong growth in Revenue. The Revenue will grow by 25.15% on average per year.
EPS Next Y-213.93%
EPS Next 2Y-82.89%
EPS Next 3Y-53.96%
EPS Next 5YN/A
Revenue Next Year-3.47%
Revenue Next 2Y23.5%
Revenue Next 3Y9.94%
Revenue Next 5Y25.15%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
ALCLS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALCLS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as ALCLS's earnings are expected to decrease with -53.96% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-82.89%
EPS Next 3Y-53.96%
5. Dividend
5.1 Amount
No dividends for ALCLS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EPA:ALCLS (11/7/2025, 7:00:00 PM)
2.86
-0.01 (-0.35%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners15.56%
Inst Owner ChangeN/A
Ins Owners2.82%
Ins Owner ChangeN/A
Market Cap286.93M
Revenue(TTM)49.22M
Net Income(TTM)-100.18M
Analysts84.62
Price Target6.63 (131.82%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.93%
Min EPS beat(2)4.37%
Max EPS beat(2)25.48%
EPS beat(4)4
Avg EPS beat(4)48.46%
Min EPS beat(4)4.37%
Max EPS beat(4)145.69%
EPS beat(8)7
Avg EPS beat(8)30.86%
EPS beat(12)9
Avg EPS beat(12)22.27%
EPS beat(16)12
Avg EPS beat(16)21.54%
Revenue beat(2)1
Avg Revenue beat(2)21.17%
Min Revenue beat(2)-20.05%
Max Revenue beat(2)62.39%
Revenue beat(4)3
Avg Revenue beat(4)64.94%
Min Revenue beat(4)-20.05%
Max Revenue beat(4)161.56%
Revenue beat(8)5
Avg Revenue beat(8)33.5%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)6.88%
EPS NY rev (1m)0%
EPS NY rev (3m)6.32%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-8.53%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.93%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 3.55 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 3.42 | ||
| P/tB | 3.46 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.29
EYN/A
EPS(NY)-1.01
Fwd EYN/A
FCF(TTM)-0.32
FCFYN/A
OCF(TTM)-0.29
OCFYN/A
SpS0.81
BVpS0.84
TBVpS0.83
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -28.3% | ||
| ROE | -103.16% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 3.66% | ||
| FCFM | N/A |
ROA(3y)-26.82%
ROA(5y)-25.52%
ROE(3y)-79.12%
ROE(5y)-63.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.26
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.91 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 16.04% | ||
| Cap/Sales | 3.51% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.38 | ||
| Quick Ratio | 1.38 | ||
| Altman-Z | -0.62 |
F-Score3
WACC6.25%
ROIC/WACCN/A
Cap/Depr(3y)12.8%
Cap/Depr(5y)139.39%
Cap/Sales(3y)9.66%
Cap/Sales(5y)33.81%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)70.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%104.35%
EPS Next Y-213.93%
EPS Next 2Y-82.89%
EPS Next 3Y-53.96%
EPS Next 5YN/A
Revenue 1Y (TTM)435.37%
Revenue growth 3Y8.44%
Revenue growth 5Y16.44%
Sales Q2Q%105.87%
Revenue Next Year-3.47%
Revenue Next 2Y23.5%
Revenue Next 3Y9.94%
Revenue Next 5Y25.15%
EBIT growth 1Y46.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-33.31%
EBIT Next 3Y-33.24%
EBIT Next 5Y-29.24%
FCF growth 1Y51.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y55.32%
OCF growth 3YN/A
OCF growth 5YN/A
CELLECTIS / ALCLS.PA FAQ
Can you provide the ChartMill fundamental rating for CELLECTIS?
ChartMill assigns a fundamental rating of 2 / 10 to ALCLS.PA.
Can you provide the valuation status for CELLECTIS?
ChartMill assigns a valuation rating of 0 / 10 to CELLECTIS (ALCLS.PA). This can be considered as Overvalued.
What is the profitability of ALCLS stock?
CELLECTIS (ALCLS.PA) has a profitability rating of 1 / 10.